Athena Athena

X
[{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Life Sciences Innovation Center Announces Data from Phase I Study of its Ulcerative Colitis Treatment LC51-0255","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"LG Chem","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","amount":"$453.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta and LG Chem Life Sciences Expand Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","amount":"$453.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Renews License Triggering Payment to Avacta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"LG Chem","sponsor":"MaxCyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Enters Final Stage of Clinical Development for New Gout Drug","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","amount":"$566.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$95.5 million","upfrontCash":"$10.0 million","newsHeadline":"Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III"},{"orgOrder":0,"company":"LG Chem","sponsor":"UNICEF","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem to Supply UNICEF with $200 Million Worth of Essential Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","amount":"$305.0 million","upfrontCash":"$100.0 million","newsHeadline":"Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by LG Chem

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the agreement, Rhythm will acquire global rights for LB54640, an investigational oral small molecule MC4R agonist now in Phase 2 clinical trials for patients with acquired hypothalamic obesity and proopiomelanocortin, LEPR, or PCSK1 deficiency obesity.

            Lead Product(s): LB54640

            Therapeutic Area: Nutrition and Weight Loss Product Name: LB54640

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Rhythm Pharmaceuticals

            Deal Size: $305.0 million Upfront Cash: $100.0 million

            Deal Type: Licensing Agreement January 04, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, LG Chem will supply UNICEF with its polio vaccine Eupolio and a pentavalent vaccine Eupenta that prevents diphtheria, pertussis, tetanus, hepatitis B and meningitis to solve global public health issues.

            Lead Product(s): Sabin Inactivated Polio Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Eupolio

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: UNICEF

            Deal Size: $200.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.

            Lead Product(s): Tigulixostat

            Therapeutic Area: Rheumatology Product Name: LC350189

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Innovent Biologics

            Deal Size: $95.5 million Upfront Cash: $10.0 million

            Deal Type: Collaboration December 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AVEO will establish LG Chem’s commercial presence in oncology through AVEO’s lead product, FOTIVDA® (tivozanib), which received U.S. FDA approval for the treatment of relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.

            Lead Product(s): Tivozanib

            Therapeutic Area: Oncology Product Name: Fotivda

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Aveo Oncology

            Deal Size: $566.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition October 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the placebo group.

            Lead Product(s): Tigulixostat

            Therapeutic Area: Rheumatology Product Name: LC350189

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LG203003 is second NASH compound is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage.

            Lead Product(s): LG203003

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LG203003

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeutic.

            Lead Product(s): LR19023

            Therapeutic Area: Oncology Product Name: LR19023

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Recipient: MaxCyte

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 12, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avacta’s Affimer® PD-L1 inhibitor (PD-L1 XT) with Affimer XT™ serum half-life extension for a range of indications.

            Lead Product(s): PD-L1 XT

            Therapeutic Area: Oncology Product Name: PD-L1 XT

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: Avacta Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration June 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership provides LG Chem with rights to develop and commercialise other Affimer® and non-Affimer biotherapeutics combined with Affimer XT® half-life extension for a range of indications.

            Lead Product(s): PD-L1 XT

            Therapeutic Area: Oncology Product Name: PD-L1 XT

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: Avacta Group

            Deal Size: $453.5 million Upfront Cash: Undisclosed

            Deal Type: Partnership September 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.

            Lead Product(s): TT-01025

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TT-01025

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: TransThera Biosciences

            Deal Size: $350.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 18, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY